Participants assigned to a lifestyle intervention program or metformin treatment designed to help prevent or delay type 2 diabetes onset attained well-being scores of 6.81 and 6.69, respectively, compared with only 6.67 in those who had placebo treatment, a study in Diabetes Care revealed. Researchers also found that lifestyle intervention and metformin treatment resulted in higher cumulative direct medical costs, but showed greater efficacy than placebo therapy.

Related Summaries